Last updated: February 15, 2026
Overview of the Drug
NDC 00228-3087 corresponds to Sotrastaurin (AEB071), an immunosuppressant developed for preventing organ rejection in transplant patients. Its primary mechanism involves inhibiting protein kinase C (PKC), which affects T-cell activation.
Current Market Position
Sotrastaurin entered clinical development with promising results but has faced competition from established immunosuppressants such as tacrolimus, mycophenolate mofetil, and sirolimus. Its commercialization status varies across regions:
- Regulatory Status: Not approved by FDA as of 2023; development discontinued or delayed in several markets.
- Pipeline Status: Phase 3 trials completed in specific indications, with some FDA submissions withdrawn or halted.
- Market Availability: Limited to ongoing or completed trials; not widely available commercially.
Market Size and Demand Drivers
The global transplant immunosuppressant market is projected to grow from $4.2 billion in 2022 to approximately $6.1 billion by 2028, CAGR 6.5%. Key segments include kidney, liver, and heart transplants, with immunosuppressant drugs accounting for most therapeutic treatments.
In the absence of formal approval, direct market demand for Sotrastaurin remains speculative but could serve niche uses or off-label applications if approved.
Competitive Landscape
Major competitors include:
- Tacrolimus (brand: Prograf): dominant, with over 50% market share.
- Mycophenolate mofetil (CellCept): significant presence.
- Sirolimus (Rapamune): lower but stable market share.
Sotrastaurin's potential advantages include a different side effect profile and possible reduced nephrotoxicity, which may attract some market segments if approved.
Price Projections and Revenue Estimates
Due to the drug's developmental status and lack of FDA approval, current market prices are not established. However, general pricing for comparable immunosuppressants indicates:
| Drug |
Average Wholesale Price (AWP) per month |
Market Share Approximate |
| Tacrolimus |
$300–$400 |
50-60% |
| Mycophenolate |
$400–$600 |
20-25% |
| Sirolimus |
$250–$350 |
10-15% |
If Sotrastaurin gains approval and captures even 5-10% of the segment, revenues could range from $200 million to $600 million annually, assuming rivalling existing drugs’ price points.
Pricing Strategy Considerations
- Pricing Premium: Sotrastaurin could command a 10-20% premium over similar drugs if it proves superior in efficacy or safety.
- Market Penetration: Launch strategies should focus on transplant centers emphasizing improved outcomes or reduced side effects.
Factors Affecting Price and Market Penetration
- Regulatory approvals and safety profile.
- Competitive positioning against incumbent drugs.
- Payer acceptance and reimbursement policies.
- Distributor and hospital procurement agreements.
Conclusion
Without FDA or EMA approval, Sotrastaurin’s market remains limited. Should future regulatory approval occur, projected revenues could reach hundreds of millions, with strategic pricing around existing immunosuppressants. Vigilance on development updates and regulatory decisions is critical for accurate outlooks.
Key Takeaways
- NDC 00228-3087 refers to Sotrastaurin, a PKC inhibitor immunosuppressant.
- It faces significant competition from established transplant drugs with active market share.
- Current market demand is hypothetical; real revenues depend on regulatory approval.
- Price projections suggest $200 million to $600 million annual revenues upon commercialization.
- Regulatory, safety, and reimbursement factors will heavily influence market entry success.
FAQs
1. What is the current regulatory status of Sotrastaurin?
Sotrastaurin has completed some late-phase trials but lacks FDA approval as of 2023. Development has been halted or delayed in multiple markets.
2. How does the pricing of Sotrastaurin compare to existing immunosuppressants?
Pricing remains speculative; comparable drugs cost $300–$600 monthly. If approved, Sotrastaurin's price may be set within this range or slightly higher.
3. What markets could Sotrastaurin target if approved?
Primarily kidney, liver, and heart transplant patients. It could also serve niche autoimmune indications.
4. What factors could influence Sotrastaurin’s market success?
Regulatory approval, safety profile, comparative efficacy, physician acceptance, and reimbursement policies.
5. How does competitive pressure affect revenue potential?
Dominance of tacrolimus and mycophenolate limits market share. Sotrastaurin needs a clear clinical advantage to secure substantial sales.
References
[1] Market data from Grand View Research, "Immunosuppressants Market Size, Share & Trends Analysis," 2022.
[2] U.S. FDA Drug Approvals and Pending Investigations, 2023.
[3] EvaluatePharma, "Global Immunosuppressants Market Forecast," 2022.
